Neurology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Correspondence:
Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Giovannoni, G.
Right arrow Articles by Goodman, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Giovannoni, G.
Right arrow Articles by Goodman, A.
Related Collections
Right arrow All Immunology
Right arrow Autoimmune diseases
Right arrow Multiple sclerosis
Right arrowRelated Articles
Neurology, Vol. 65, Issue 1, 6-8, July 12, 2005

EDITORIALS

Neutralizing anti-IFN-ß antibodies: How much more evidence do we need to use them in practice?

Gavin Giovannoni and Andrew Goodman

You have reached the most complete version of this article accessible without further authentication.
More complete versions are available.
Link to article

Article topics:


Related Articles

July 12 Highlights
Neurology 2005 65: 2-3. [Full Text] [PDF]

Appearance and disappearance of neutralizing antibodies during interferon-beta therapy
P. Soelberg Sorensen, N. Koch-Henriksen, C. Ross, K. M. Clemmesen, K. Bendtzen, and the Danish Multiple Sclerosis Study Group
Neurology 2005 65: 33-39. [Abstract] [Full Text] [PDF]

Neutralizing antibodies and efficacy of interferon ß-1a: A 4-year controlled study
L. Kappos, M. Clanet, M. Sandberg-Wollheim, E. W. Radue, H. P. Hartung, R. Hohlfeld, J. Xu, D. Bennett, A. Sandrock, S. Goelz, and the European Interferon Beta-1a IM Dose-Comparison Study Investigators
Neurology 2005 65: 40-47. [Abstract] [Full Text] [PDF]

Interferon ß-1a in MS: Results following development of neutralizing antibodies in PRISMS
Gordon S. Francis, George P.A. Rice, Jonathan C. Alsop for the PRISMS (Prevention of Relapses and Disability by Interferon ß-1a Subcutaneously in Multiple Sclerosis) Study Group
Neurology 2005 65: 48-55. [Abstract] [Full Text] [PDF]



This article has been cited by other articles:


Home page
 Mult SclerHome page
M Ravnborg, K Bendtzen, O Christensen, P. Jensen, D Hesse, M. Tovey, and P. Sorensen
Treatment with azathioprine and cyclic methylprednisolone has little or no effect on bioactivity in anti-interferon beta antibody-positive patients with multiple sclerosis
Multiple Sclerosis, March 1, 2009; 15(3): 323 - 328.
[Abstract] [PDF]

Home page
 Therapeutic Advances in Neurological DisordersHome page
P. Soelberg Sorensen
Review: Neutralizing antibodies against interferon-beta
Therapeutic Advances in Neurological Disorders, September 1, 2008; 1(2): 125 - 141.
[Abstract] [PDF]

Home page
 Mult SclerHome page
R. Farrell, R. Kapoor, S. Leary, P. Rudge, A. Thompson, D. Miller, and G. Giovannoni
Neutralizing anti-interferon beta antibodies are associated with reduced side effects and delayed impact on efficacy of Interferon-beta
Multiple Sclerosis, March 1, 2008; 14(2): 212 - 218.
[Abstract] [PDF]

Home page
 NeurologyHome page
M. S. Freedman and A. R. Pachner
Neutralizing antibodies to biological therapies: A "touch of gray" vs a "black and white" story
Neurology, October 2, 2007; 69(14): 1386 - 1387.
[Full Text] [PDF]

Home page
 Mult SclerHome page
F. Blanchette
Clinical significance of glatiramer acetate antibodies
Multiple Sclerosis, May 1, 2007; 13(1_suppl): 28 - 35.
[Abstract] [PDF]

Home page
 Mult SclerHome page
J. Oger and E. Gibbs
Binding antibodies: Vancouver's perspective
Multiple Sclerosis, May 1, 2007; 13(1_suppl): 36 - 43.
[Abstract] [PDF]

Home page
 Mult SclerHome page
A.T. Reder
Neutralizing antibodies in multiple sclerosis: a complex impact on interferon responses, magnetic resonance imaging findings and clinical outcomes
Multiple Sclerosis, May 1, 2007; 13(1_suppl): 53 - 62.
[Abstract] [PDF]

Home page
 BMJHome page
T J Murray
Diagnosis and treatment of multiple sclerosis.
BMJ, March 4, 2006; 332(7540): 525 - 527.
[Full Text] [PDF]

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Correspondence:
Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Giovannoni, G.
Right arrow Articles by Goodman, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Giovannoni, G.
Right arrow Articles by Goodman, A.
Related Collections
Right arrow All Immunology
Right arrow Autoimmune diseases
Right arrow Multiple sclerosis
Right arrowRelated Articles